StockTipsArenaBeta

BUY Lupin Limited — BOB Capital Markets

BUYLupin Limited
Lupin share price target & all analyst calls

byBOB Capital MarketsHorizon: NA (inferred 1 year)10 May 2026via Institutional / Brokerage Research

Entry₹2,379.5Inferred
Target₹2,900
Total upside +21.87%
Stop lossNot given
CMP₹1,9228h ago
Active-19.23%+50.88%upside left 7 mo left
Follow BOB Capital Markets for new calls(63% target hit, 357 closed calls)Get alertsWatch LUPIN for new buy/sell callsGet alertsSee 11 other Long-term calls on LUPINSee 214 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 23 Oct, 1:03 am IST
54 supporting5 neutral10 opposing
Supports the BUY call (54)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·22 Oct · today

Lupin gets US FDA nod for vitamin K injection with $52 million US market

NewsCnbc-Tv18·8 Oct · 2w ago

(opens in new tab)

Lupin received U.S. FDA approval for its Phytonadione Injectable Emulsion, USP.

BSE · Company Update·8 Oct · 2w ago

(opens in new tab)

Lupin has launched Formoflo-G MDI, the world's first fixed-dose triple combination drug for the management of Chronic Obstructive Pulmonary Disease (COPD).

BSE · Company Update·6 Oct · 2w ago

(opens in new tab)

Lupin Ltd has increased its stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI) through a share buyback, making MPPI a step-down wholly owned subsidiary.

BSE · Company Update·1 Oct · 3w ago

(opens in new tab)
Neutral / worth noting (5)

Q2 FY27 results scheduled — board meets 03 Nov 2026

BSE · Board Meeting·In 11 days

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 3d ago

(opens in new tab)
Weighs against the BUY call (10)

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·27 Aug · 2mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Lupin

All analyst calls on Lupin

More from BOB Capital Markets

Every call and its outcome